Beyond cisplatin: Combination therapy with arsenic trioxide

Miodragović, Ðenana; Swindell, Elden P.; Waxali, Zohra Sattar; Bogachkov, Abraham; O’Halloran, Thomas V.

doi:10.1016/j.ica.2019.119030

Cited by 26 publications

(18 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Arsenic trioxide and cisplatin in nanoscale delivery systems showed synergistic anticancer effects. 30 Arsenic nanoparticles were safer than arsenic trioxide with equivalent efficacy against breast cancer cell lines. 31 It seems as if arsenic acts as a double-edged sword and, depending on the biological states of cell and arsenic concentration, diverse effects would be displayed.…”

Section: Discussionmentioning

confidence: 99%

Subcellular Organelle Toxicity Caused by Arsenic Nanoparticles in Isolated Rat Hepatocytes

Jahangirnejad

Goudarzi

Kalantari‬

et al. 2020

Int J Occup Environ Med

View full text Add to dashboard Cite

Background: Arsenic, an environmental pollutant, is a carcinogenic metalloid and also an anticancer agent. Objective: To evaluate the toxicity of arsenic nanoparticles in rat hepatocytes. Methods: Freshly isolated rat hepatocytes were exposed to 0, 20, 40, and 100 µM of arsenic nanoparticles and its bulk counterpart. Their viability, reactive oxygen species level, glutathione depletion, mitochondrial and lysosomal damage, and apoptosis were evaluated. Results: By all concentrations, lysosomal damage and apoptosis were clearly evident in hepatocytes exposed to arsenic nanoparticles. Evaluation of mitochondria and lysosomes revealed that lysosomes were highly damaged. Conclusion: Exposure to arsenic nanoparticles causes apoptosis and organelle impairment. The nanoparticles have potentially higher toxicity than the bulk arsenic. Lysosomes are highly affected. It seems that, instead of mitochondria, lysosomes are the first target organelles involved in the toxicity induced by arsenic nanoparticles.

show abstract

Section: Discussionmentioning

confidence: 99%

Subcellular Organelle Toxicity Caused by Arsenic Nanoparticles in Isolated Rat Hepatocytes

Jahangirnejad

Goudarzi

Kalantari‬

et al. 2020

Int J Occup Environ Med

View full text Add to dashboard Cite

show abstract

“…Two crystal structures similar to (1) were found after a search of the Cambridge Structure Database (CSD, Version 5.40, update of November 2019; Groom et al, 2016), both of which (ODOHAS, ODOHEW) were reported by Miodragović et al (2013Miodragović et al ( , 2019. They consist of the same arsenoplatin complex as (1), accompanied by an acetamide hemihydrate and acetamide solvent species in the unit cell, and crystallize in the P1 and P2 1 /n space groups, respectively.…”

Section: Database Surveymentioning

confidence: 98%

“…Arsenic trioxide was approved by the FDA in 2000 for the treatment of acute promyelocytic leukemia, and since then several studies have shown that the combinatorial employment of arsenic and platinum-based cancer drugs has shown significant therapeutic potential (Wang et al, 2004;Shen et al, 2004;Emadi & Gore, 2010;Zhang et al, 2009Zhang et al, , 2010. These results led to the synthesis of complexes containing both platinum and arsenic (Swindell et al, 2013;Miodragović et al, 2013Miodragović et al, , 2019, which were called arsenoplatins. Initial results indicate that these complexes are able to bypass drug-resistance mechanisms that lower the effect of cisplatin and have higher cytotoxicity than cisplatin in some cases.…”

Section: Chemical Contextmentioning

confidence: 99%

See 1 more Smart Citation

Crystal structures of chlorido[dihydroxybis(1-iminoethoxy)]arsanido-κ³ N,As,N′]platinum(II) and of a polymorph of chlorido[dihydroxybis(1-iminopropoxy)arsanido-κ³ N,As,N′]platinum(II)

et al. 2020

View full text Add to dashboard Cite

Each central platinum(II) atom in the crystal structures of chlorido[dihydroxybis(1-iminoethoxy)arsanido-κ3 N,As,N′]platinum(II), [Pt(C4H10AsN2O4)Cl] (1), and of chlorido[dihydroxybis(1-iminopropoxy)arsanido-κ3 N,As,N′]platinum(II), [Pt(C6H14AsN2O4)Cl] (2), is coordinated by two nitrogen donor atoms, a chlorido ligand and to arsenic, which, in turn, is coordinated by two oxygen donor ligands, two hydroxyl ligands and the platinum(II) atom. The square-planar and trigonal–bipyramidal coordination environments around platinum and arsenic, respectively, are significantly distorted with the largest outliers being 173.90 (13) and 106.98 (14)° for platinum and arsenic in (1), and 173.20 (14)° and 94.20 (9)° for (2), respectively. One intramolecular and four classical intermolecular hydrogen-bonding interactions are observed in the crystal structure of (1), which give rise to an infinite three-dimensional network. A similar situation (one intramolecular and four classical intermolecular hydrogen-bonding interactions) is observed in the crystal structure of (2). Various π-interactions are present in (1) between the platinum(II) atom and the centroid of one of the five-membered rings formed by Pt, As, C, N, O with a distance of 3.7225 (7) Å, and between the centroids of five-membered (Pt, As, C, N, O) rings of neighbouring molecules with distances of 3.7456 (4) and 3.7960 (6) Å. Likewise, weak π-interactions are observed in (2) between the platinum(II) atom and the centroid of one of the five-membered rings formed by Pt, As, C, N, O with a distance of 3.8213 (2) Å, as well as between the Cl atom and the centroid of a symmetry-related five-membered ring with a distance of 3.8252 (12) Å. Differences between (2) and the reported polymorph [Miodragović et al. (2013). Angew. Chem. Int. Ed. 52, 10749–10752] are discussed.

show abstract

“…In 2001, US FDA and in 2002 EU commission approved an arsenic trioxide drug for its high effectiveness in the treatment of acute and promyelocytic leukemia (Au 2011;Chen et al 2011;Iland and Seymour 2013;Liu et al 2012). Recently As 2 O 3 has also been proposed as a promising candidate for lung cancer treatment, alone or in combination with the classic cisplatin drug (Huang and Zeng 2019;Medici et al 2015;Miodragović et al 2019;Yang et al 2019). The synergic effect of As 2 O 3 with a B cell lymphoma-2 (Bcl-2) family inhibitor (ABT-737) in uterine cervical cancer cells was also evidenced to ameliorate ABT-737 target therapy (Hsin et al 2019).…”

Section: Use Of Arsenic In Medicinementioning

confidence: 99%

Arsenic intoxication: general aspects and chelating agents

et al. 2020

View full text Add to dashboard Cite

Arsenic (As) is widely used in the modern industry, especially in the production of pesticides, herbicides, wood preservatives, and semiconductors. The sources of As such as contaminated water, air, soil, but also food, can cause serious human diseases. The complex mechanism of As toxicity in the human body is associated with the generation of free radicals and the induction of oxidative damage in the cell. One effective strategy in reducing the toxic effects of As is the usage of chelating agents, which provide the formation of inert chelator-metal complexes with their further excretion from the body. This review discusses different aspects of the use of metal chelators, alone or in combination, in the treatment of As poisoning. Consideration is given to the therapeutic effect of thiol chelators such as meso-2,3-dimercaptosuccinic acid, sodium 2,3-dimercapto-1-propanesulfonate, 2,3-dimercaptopropanol, penicillamine, ethylenediaminetetraacetic acid, and other recent agents against As toxicity. The review also considers the possible role of flavonoids, trace elements, and herbal drugs as promising natural chelating and detoxifying agents.

show abstract

Beyond cisplatin: Combination therapy with arsenic trioxide

Cited by 26 publications

References 130 publications

Subcellular Organelle Toxicity Caused by Arsenic Nanoparticles in Isolated Rat Hepatocytes

Subcellular Organelle Toxicity Caused by Arsenic Nanoparticles in Isolated Rat Hepatocytes

Crystal structures of chlorido[dihydroxybis(1-iminoethoxy)]arsanido-κ³ N,As,N′]platinum(II) and of a polymorph of chlorido[dihydroxybis(1-iminopropoxy)arsanido-κ³ N,As,N′]platinum(II)

Arsenic intoxication: general aspects and chelating agents

Contact Info

Product

Resources

About

Beyond cisplatin: Combination therapy with arsenic trioxide

Cited by 26 publications

References 130 publications

Subcellular Organelle Toxicity Caused by Arsenic Nanoparticles in Isolated Rat Hepatocytes

Subcellular Organelle Toxicity Caused by Arsenic Nanoparticles in Isolated Rat Hepatocytes

Crystal structures of chlorido[dihydroxybis(1-iminoethoxy)]arsanido-κ3 N,As,N′]platinum(II) and of a polymorph of chlorido[dihydroxybis(1-iminopropoxy)arsanido-κ3 N,As,N′]platinum(II)

Arsenic intoxication: general aspects and chelating agents

Contact Info

Product

Resources

About

Crystal structures of chlorido[dihydroxybis(1-iminoethoxy)]arsanido-κ³ N,As,N′]platinum(II) and of a polymorph of chlorido[dihydroxybis(1-iminopropoxy)arsanido-κ³ N,As,N′]platinum(II)